Skip to main content
OpenTrials
Completed

NCT Number: NCT03827408

Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment

The aim of the study is to evaluate the effect of nebulized Midazolam, Dexmedetomidine, and their combination as procedural, moderate sedative agents in preschoolers undergoing dental treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

4 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Faculty of Dentistry, Alexandria University

Alexandria, 21512, Egypt

About this study

Dental anxiety and fear related behaviors are global problems in Pediatric Dentistry. Preschoolers represent a dental behavior management problem and there is always a debate over the best behavioral management technique for preschoolers undergoing dental treatment. Moderate sedation is considered as an acceptable option.

Children who need treatment under local anesthesia, for thirty minutes will be included in the study. A total of 72 uncooperative pediatric dental patients, of age range 4-6 years, will be selected from the Pediatric Dentistry and Dental Public Health Department, Faculty of Dentistry, Alexandria University, Egypt. The participants will be randomly allocated into 3 groups that will undergo a procedural sedation session via a nebulizer. Children of group I will receive nebulized solution of 0.5 mg/kg Midazolam, Group II will receive nebulized solution of 5µg/kg Dexmedetomidine, and Group III will receive a nebulized solution of 0.3 mg/kg Midazolam and 3µg/kg Dexmedetomidine respectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range 4-6 years
  • Frankl scale score 2.
  • ASA I or II physical status.
  • Dental intervention under local anesthesia not requiring more than 30 minutes.
  • No previous dental experience.
  • Parent/guardian"s written consent.

Exclusion criteria

  • Dental treatment indicated under general anesthesia.
  • Presence of facial deformities.
  • History of neurological or cognitive alterations.
  • Mouth breathers.

Treatment and study plan

Midazolam group (MDZ)

Drug

IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland

Dexmedetomidine group (DEX)

Drug

IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.

Combination of Midazolam and Dexmedetomidine (MDZ/DEX)

Drug

Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(

Primary outcomes

  1. Facemask acceptance during drug delivery

    Time frame: during the sedation procedure

    It will be evaluated according to Zanaty & Metainy as: poor (terrified, crying and combative), fair (moderate fear of mask not calmed with reassurance), good (slight fear of mask, easily reassured) or excellent (unafraid, cooperative and accepts mask readily)

  2. Effect of sedation on children's future behavior

    Time frame: after one week in the follow-up session

    Each child's behavior will be reassessed in the follow-up sessions and compared to that at baseline (before dental treatment) using Frankl scale (ranges from 0-4)

  3. The 'ease of treatment completion' sing separate five-point scales.

    Time frame: immediately after completion of the dental treatment procedures.

    This will be measured using separate five-point scales according to Surendar et al: Score 5 indicates an excellent quiet and cooperative child while score 1 indicates Prohibitive active resistance and crying; treatment cannot be rendered.

  4. Post-operative effects of the sedation

    Time frame: immediately after completion of the dental treatment procedures.

    This will be assessed according to Modified Vernon et al.

  5. Analgo-sedative effect of each drug

    Time frame: during the sedation procedure (time taken from drug administration till reaching satisfactory sedation)

    Onset of Sedation from drug administration until the onset of satisfactory sedation

  6. Analgo-sedative effect of each drug

    Time frame: during the sedation procedure (after drug administration until reaching satisfactory sedation)

    Sedation level using Modified Observer's Assessment of Alertness/Sedation Scale. The scale is composed of 4 categories (each has scores ranging from 1-5). The categories are responsiveness, speech, facial expression and eyes. The final score is the sum of scores: the totally awake score is 20/20 and the deeply sedated score is 9/20

  7. Analgo-sedative effect of each drug

    Time frame: during local anesthesia injection to start the operative procedure

    The analgesic effect of the sedative drugs will be assessed using "Face, Legs, Activity, Cry, Consolability" scale (FLACC). The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.

  8. Analgo-sedative effect of each drug

    Time frame: during the sedation procedure (from its onset till meeting discharge criteria)

    The duration of sedation: defined as the onset of satisfactory sedation until the time of meeting discharge criteria according to the American Academy of Pediatric Dentistry.

  9. Analgo-sedative effect of each drug.

    Time frame: during the sedation procedure (from its onset till meeting discharge criteria)

    Assessment of the most common procedural side effects such as (hypoxia, respiratory depression, agitation, arrhythmia, bradycardia, hypotension or hypertension, shivering, nausea and vomiting) will be recorded.

  10. Amnesic effect of sedative agents.

    Time frame: immediately after completion of the dental treatment procedures.

    Anterograde amnesia: will be assessed according to a modification of Bulach et al.

  11. Hemodynamic response of sedative agents.

    Time frame: during the sedation procedure (from its onset till meeting discharge criteria)

    Vital sign: Blood pressure (in mmHg) will be monitored using a sphygmomanometer.

  12. Hemodynamic response of sedative agents.

    Time frame: during the sedation procedure (from its onset till meeting discharge criteria)

    Vital sign: Heart rate will be counted

  13. Hemodynamic response of sedative agents.

    Time frame: during the sedation procedure (from its onset till meeting discharge criteria)

    Vital sign: Oxygen saturation will be monitored using an oximeter

Sponsors and collaborators

Lead sponsor

Nourhan M.Aly

Other

Collaborators

  • Alexandria University

Registry information

Official study title

Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment: A Randomized Clinical Trial

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Feb 1, 2019
Registry last updated
Jan 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.